Want to see SINT full AI Analyst Report?
Top Page
Sintx Technologies
(NASDAQ:SINT)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▼(-59.89% Downside)
Action:Reiterated
Date:07/14/26
The score is held down primarily by very weak financial performance (negative gross margin, extremely large losses versus a small revenue base, and significant cash burn) and a deteriorating equity cushion. Technicals add further pressure with a pronounced downtrend, partially offset by oversold readings. Valuation provides limited support because the company is unprofitable (negative P/E) and no dividend yield is indicated.
Positive Factors
Proprietary silicon nitride technology
Sintx's focus on silicon nitride (Si3N4) gives it a durable technology differentiation in medical implants and advanced materials. Proprietary material properties create high technical barriers to entry, supporting a long-term niche competitive position and potential cross-industry applications as commercialization progresses.
Negative Factors
Severe and persistent cash burn
Operating and free cash flow are deeply negative (~-$9.8M TTM), indicating ongoing cash consumption that erodes reserves. Persistent burn forces repeated financings, increases dilution risk, and constrains investments in commercialization and scale-up, undermining long-term independent viability without profitable operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary silicon nitride technology
Sintx's focus on silicon nitride (Si3N4) gives it a durable technology differentiation in medical implants and advanced materials. Proprietary material properties create high technical barriers to entry, supporting a long-term niche competitive position and potential cross-industry applications as commercialization progresses.
Read all positive factors
Sintx Technologies (SINT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.81M
Dividend YieldN/A
Average Volume (3M)148.79K
Price to Earnings (P/E)―
Beta (1Y)2.65
Revenue Growth-59.95%
EPS Growth56.67%
CountryUS
Employees32
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-5.63
Shares Outstanding6,357,630
10 Day Avg. Volume107,243
30 Day Avg. Volume148,787
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)3.66
Price to Sales (P/S)10.52
P/FCF Ratio-1.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.00Price Target Upside113.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.14
Revenue Forecast (FY)$2.04M
Sintx Technologies Business Overview & Revenue Model
Company Description
Sintx Technologies, Inc. is an advanced materials enterprise dedicated to researching, developing, and commercializing medical devices crafted from silicon nitride. These innovative products serve biomedical, industrial, and antipathogenic uses, p...
How the Company Makes Money
null...
Sintx Technologies Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.03M | 1.02M | 1.25M | 2.63M | 601.00K | 606.00K |
| Gross Profit | -336.00K | -201.00K | 435.00K | 1.84M | 336.00K | 157.00K |
| EBITDA | -10.22M | -9.65M | -9.61M | -6.60M | -11.06M | -8.63M |
| Net Income | -17.61M | -17.08M | -11.02M | -8.26M | -12.04M | -9.31M |
Balance Sheet | ||||||
| Total Assets | 7.81M | 9.51M | 9.41M | 15.37M | 15.77M | 21.84M |
| Cash, Cash Equivalents and Short-Term Investments | 1.89M | 4.14M | 3.60M | 3.34M | 6.25M | 14.27M |
| Total Debt | 3.26M | 3.25M | 4.03M | 4.76M | 3.63M | 2.91M |
| Total Liabilities | 6.91M | 6.58M | 5.52M | 6.59M | 10.07M | 4.64M |
| Stockholders Equity | 904.00K | 2.93M | 3.89M | 8.77M | 5.70M | 17.20M |
Cash Flow | ||||||
| Free Cash Flow | -9.89M | -8.76M | -9.33M | -14.64M | -11.67M | -13.87M |
| Operating Cash Flow | -9.76M | -8.57M | -8.64M | -14.12M | -10.26M | -10.13M |
| Investing Cash Flow | 969.00K | 913.00K | -194.00K | -501.00K | -1.10M | -1.66M |
| Financing Cash Flow | 4.18M | 8.20M | 9.09M | 11.71M | 3.34M | 705.00K |
Sintx Technologies Technical Analysis
Neutral
3.74
Price Trends
1.90
Negative
2.21
Negative
2.82
Negative
Market Momentum
-0.08
Negative
54.45
Neutral
79.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SINT, the sentiment is Neutral. The current price of 3.74 is above the 20-day moving average (MA) of 1.61, above the 50-day MA of 1.90, and above the 200-day MA of 2.82, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 54.45 is Neutral, neither overbought nor oversold. The STOCH value of 79.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SINT.
Sintx Technologies Risk Analysis
Sintx Technologies disclosed 38 risk factors in its most recent earnings report. Sintx Technologies reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sintx Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $18.17B | 24.27 | 6.01% | 1.05% | 9.23% | -14.66% | |
72 Outperform | $124.86B | 33.47 | 15.10% | 1.05% | 8.48% | 27.36% | |
68 Neutral | $109.30B | 22.77 | 9.85% | 3.43% | 8.43% | 3.17% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.29B | -180.59 | -0.69% | ― | 1.60% | 98.56% | |
49 Neutral | $476.98M | -7.84 | -13.44% | ― | 2.59% | 59.39% | |
42 Neutral | $10.81M | -0.30 | -592.55% | ― | -59.95% | 56.67% |
* Healthcare Sector Average
SINT
Sintx Technologies
1.77
-0.89
-33.46%
IART
Integra Lifesciences
17.88
5.15
40.46%
MDT
Medtronic
86.68
-0.17
-0.19%
OFIX
Orthofix Medical
12.26
-0.05
-0.41%
SYK
Stryker
341.20
-35.82
-9.50%
ZBH
Zimmer Biomet Holdings
96.98
5.89
6.46%
Sintx Technologies Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Sintx Technologies Restructures Warrants and Equity Positions
Neutral
Jul 2, 2026
On June 29, 2026, Sintx Technologies and MedTech Ceramics, LP executed a letter agreement to resolve the disposition of 507,254 common shares held in abeyance from a September 2025 warrant inducement and to overhaul the holder’s warrant posi...
Business Operations and StrategyPrivate Placements and Financing
Sintx Technologies Announces New Private Placement Financing
Positive
Jun 3, 2026
On June 2, 2026, SINTX Technologies entered into securities purchase agreements with institutional and accredited investors for a private placement of 1,882,845 units, each comprising one common share plus Class A and Class B warrants, raising gro...
Delistings and Listing ChangesFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Sintx Technologies Faces Nasdaq Noncompliance, Plans Remediation
Negative
May 27, 2026
On May 22, 2026, SINTX Technologies received a notice from Nasdaq that it was no longer in compliance with the exchange’s requirement to maintain at least $2.5 million in stockholders’ equity, after reporting approximately $904,000 in ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.